Skip to main content
SpringerLink
Log in

CART trials are going ahead

  • Insight
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Cai, B., Guo, M., Wang, Y., Zhang, Y., Yang, J., Guo, Y., Dai, H., Yu, C., Sun, Q., Qiao, J., Hu, K., Zuo, H., Dong, Z., Zhang, Z., Feng, M., Li, B., Sun, Y., Liu, T., Liu, Z., Wang, Y., Huang, Y., Yao, B., Han, W., and Ai, H. (2016). Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol 9, 131.

    Article  PubMed  PubMed Central  Google Scholar 

  • Dai, H., Wang, Y. Lu, X., and Han, W. (2016). Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 108, pii: djv439.

    Google Scholar 

  • Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J.C., Hamieh, M., Cunanan, K.M., Odak, A., Gönen, M., and Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fedorov, V.D., Themeli, M., and Sadelain, M. (2013). PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5, 215ra172–215ra172.

    Article  Google Scholar 

  • Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., and Han, W. (2016). Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59, 468–479.

    Article  CAS  PubMed  Google Scholar 

  • Gilham, D.E., Debets, R., Pule, M., Hawkins, R.E., and Abken, H. (2012). CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18, 377–384.

    Article  CAS  PubMed  Google Scholar 

  • Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L., and June, C.H. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509–1518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hartmann, J., Schüßler-Lenz, M., Bondanza, A., and Buchholz, C.J. (2017). Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 9, 1183–1197.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Luo, C., Wei, J., and Han, W. (2016). Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. Sci China Life Sci 59, 349–359.

    Article  CAS  PubMed  Google Scholar 

  • Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L., and Grupp, S.A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507–1517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sadelain, M. (2016). Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol 41, 68–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sell, S. (2017). Cancer immunotherapy: Breakthrough or “deja vu, all over again”? Tumour Biol 39, 101042831770776.

    Article  Google Scholar 

  • Wang, X., Popplewell, L.L., Wagner, J.R., Naranjo, A., Blanchard, M.S., Mott, M.R., Norris, A.P., Wong, C.L.W., Urak, R.Z., Chang, W.C., Khaled, S.K., Siddiqi, T., Budde, L.E., Xu, J., Chang, B., Gidwaney, N., Thomas, S.H., Cooper, L.J.N., Riddell, S.R., Brown, C.E., Jensen, M.C., and Forman, S.J. (2016). Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127, 2980–2990.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang, Z., Guo, Y., and Han, W. (2017). Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell in press doi: 10.1007/s13238-017-0400-z.

    Google Scholar 

  • Zhang, T., Cao, L., Xie, J., Shi, N., Zhang, Z., Luo, Z., Yue, D., Zhang, Z., Wang, L., Han, W., Xu, Z., Chen, H., and Zhang, Y. (2015). Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6, 33961–33971.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Science and Technology Planning Project of Beijing City (Z151100003915076 to Weidong Han), the National Key Research and Development Program of China (2016YFC1303501, 2016YFC1303504 to Weidong Han) and the National Natural Science Foundation of China (81502679 to Can Luo).

Author information

Authors and Affiliations

  1. Department of Molecules & Immunology, Chinese PLA General Hospital, Medical College of PLA, Beijing, 100853, China

    Jianshu Wei & Weidong Han

Authors
  1. Jianshu Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weidong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weidong Han.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, J., Han, W. CART trials are going ahead. Sci. China Life Sci. 60, 1276–1279 (2017). https://doi.org/10.1007/s11427-017-9198-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-017-9198-1

Search

Navigation